PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC
Patients with NSCLC and low TPS/high IC scores may benefit more from Nivo+Ipi than from Pembro due to distinct genomic and immunological features, including high TMB and T<sub>reg</sub> fraction.
Authors
- Shogo Kumagai (ORCID: https://orcid.org/0009-0001-0895-6846)
- Kouya Shiraishi (ORCID: https://orcid.org/0000-0002-5821-7400)
- Yuji Uehara (ORCID: https://orcid.org/0000-0001-8047-8730)
- Takashi Kohno (ORCID: https://orcid.org/0000-0002-5371-706X)
- Jun Miyakoshi (ORCID: https://orcid.org/0009-0002-9229-2276)
- Noboru Yamamoto (ORCID: https://orcid.org/0000-0002-0787-2851)
- Yasushi Goto (ORCID: https://orcid.org/0000-0002-7437-5054)
- Akito Fukuda (ORCID: https://orcid.org/0000-0002-3225-4879)
- Katsuhiko Naoki
- Yuichiro Ohe
- Yuki Takeyasu (ORCID: https://orcid.org/0000-0003-3295-0273)
- Yukio Hosomi (ORCID: https://orcid.org/0000-0002-3849-5905)
- Yasushi Yatabe
- Takayasu Kurata (ORCID: https://orcid.org/0000-0003-4123-3567)
- Jumpei Kashima (ORCID: https://orcid.org/0000-0002-5225-9319)
- Masayuki Shirasawa (ORCID: https://orcid.org/0000-0001-9948-3441)
- Hidehito Horinouchi (ORCID: https://orcid.org/0000-0001-9090-801X)
- Shunsuke Kondo (ORCID: https://orcid.org/0000-0001-9565-117X)
- Tatsuya Yoshida (ORCID: https://orcid.org/0000-0003-4896-5824)
- Takuji Suzuki (ORCID: https://orcid.org/0000-0003-0416-6641)
- Hanako Ono (ORCID: https://orcid.org/0009-0004-7697-9849)
Institutions
- Kansai Medical University (JP)
- Chiba University (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Kitasato University Hospital (JP)
- Tokyo Women's Medical University (JP)
- National Cancer Center Hospital East (JP)
- National Cancer Research Institute (GB)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-012880
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Regeneron Pharmaceuticals
- Kissei
- Celltrion
- Eisai
- Kyowa Hakko Kirin
- Astellas Pharma
- Shionogi
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Daiichi Sankyo Europe